OTOF and deafness: After comprehensively evaluating the drug's efficacy and safety, we conducted a single center, open‐label, individual‐patient, non‐randomized controlled interventional clinical study by performing a single round window injection of AAV‐OTOF in two pediatric patients with profound deafness caused by OTOF mutations (Figure1).